Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004: 5. Country priorities for drug financing: 5.4 Thailand

Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages)

Índice de contenido

	Executive summary
		Background
		Drug financing issues
		Cost-sharing for drugs
		Monitoring for equity and quality
		Conclusions and recommendations
		Workshop evaluation
	1. Introduction
		1.1 Opening session
		1.2 Background
		1.3 Objectives of the Working Group
	2. Country presentations on drug financing
		2.1 Indonesia (presented by Dra Andayaningsih)
		2.2 Myanmar (presented by Dr Than Zaw)
		2.3 Nepal (presented by Dr Singh Karki)
		2.4 Thailand (presented by Dr Porntep Siriwanarangsun)
		2.5 Summary
	3. Korat provincial field visit
		3.1 Soongnern Community Hospital
		3.2 Maa Kleur Kao Health Centre
		3.3 Village drug funds (or drug cooperatives)
	4. Drug financing issues
		4.1 Drug financing alternatives (by Dr German Velasquez)
		4.2 Cost-sharing for drugs (by Dr Petcharat Pongcharoensuk)
		4.3 Monitoring for equity and quality (by Dr Jonathan Quick)
	5. Country priorities for drug financing
		5.1 Indonesia
		5.2 Myanmar
		5.3 Nepal
		5.4 Thailand
	6. Priorities for work group action
		6.1 Group A
		6.2 Group B
	7. Conclusions and recommendations
		7.1 Country priorities for action
		7.2 Recommendations
	Annex A. Agenda
	Annex B. List of participants
	Annex C. List of documents
	Annex D. Message from Regional Director, WHO South-East Asia Region
	Annex E. Evaluation of the meeting. Priorities for the Working Group
		1. Evaluation of the meeting
		2. Priorities for the next Working Group meeting

5.4 Thailand

1. How to reduce irrational drug use (financial mechanisms to improve use and reduce cost).

2. How to establish good data systems for drug financing in district hospitals and health centres.

3. How to introduce good drug financing systems in the private sector.

4. How to control drug prices and the number of drugs registered (the number of NED in the public and private sectors).